[go: up one dir, main page]

MXPA03002934A - Composiciones y metodos para aumentar la permeabilidad paracelular a traves de las barreras epiteliales y endoteliales. - Google Patents

Composiciones y metodos para aumentar la permeabilidad paracelular a traves de las barreras epiteliales y endoteliales.

Info

Publication number
MXPA03002934A
MXPA03002934A MXPA03002934A MXPA03002934A MXPA03002934A MX PA03002934 A MXPA03002934 A MX PA03002934A MX PA03002934 A MXPA03002934 A MX PA03002934A MX PA03002934 A MXPA03002934 A MX PA03002934A MX PA03002934 A MXPA03002934 A MX PA03002934A
Authority
MX
Mexico
Prior art keywords
compositions
methods
epithelial
paracellular permeability
subject
Prior art date
Application number
MXPA03002934A
Other languages
English (en)
Inventor
Dhiren R Thakker
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Publication of MXPA03002934A publication Critical patent/MXPA03002934A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se describen las composiciones y los metodos para aumentar la permeabilidad paracelular en un sitio de absorcion en un sujeto. El metodo incluye: (a) la administracion de una cantidad efectiva de un inhibidor de fosfolipasa C a un sujeto, a un tiempo en el cual se desea la permeabilidad paracelular aumentada; y (b) el aumento de la permeabilidad paracelular en el sujeto en el sitio de absorcion, a traves de la absorcion de la cantidad efectiva del inhibidor de fosfolipasa C. Las composiciones descritas y los metodos descritos proporcionan absorcion mejorada de un farmaco hidrofilico en un sujeto.
MXPA03002934A 2000-10-10 2001-10-10 Composiciones y metodos para aumentar la permeabilidad paracelular a traves de las barreras epiteliales y endoteliales. MXPA03002934A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23932800P 2000-10-10 2000-10-10
PCT/US2001/031501 WO2002030408A2 (en) 2000-10-10 2001-10-10 Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers

Publications (1)

Publication Number Publication Date
MXPA03002934A true MXPA03002934A (es) 2004-05-04

Family

ID=22901681

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03002934A MXPA03002934A (es) 2000-10-10 2001-10-10 Composiciones y metodos para aumentar la permeabilidad paracelular a traves de las barreras epiteliales y endoteliales.

Country Status (11)

Country Link
US (1) US7713949B2 (es)
EP (2) EP1754480B1 (es)
JP (1) JP2004532795A (es)
AT (2) ATE348622T1 (es)
AU (1) AU2002224354A1 (es)
CA (1) CA2425215C (es)
DE (2) DE60143975D1 (es)
DK (2) DK1379235T3 (es)
ES (1) ES2276847T3 (es)
MX (1) MXPA03002934A (es)
WO (1) WO2002030408A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1566447A1 (en) * 2004-02-20 2005-08-24 Aventis Pharma Deutschland GmbH Glimepiride- and insulin-induced glycosylphosphatidylinositol-specific phospholipase C regulation
US20110046079A1 (en) * 2008-01-16 2011-02-24 Mullin James M Use of Proton Pump Inhibitors as Drug Delivery Adjuvants
RU2576033C2 (ru) 2009-12-03 2016-02-27 Опко Хелс, Инк. Составы на основе гиперсулфатированных дисахаридов
CN108069929B (zh) * 2016-11-18 2021-06-15 中国科学院大连化学物理研究所 3-取代香豆素类衍生物及应用和gpr35受体的激动剂

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1511653A (en) 1974-04-16 1978-05-24 Wellcome Found Anthelmintic compositions and use
US4199507A (en) 1977-05-05 1980-04-22 The Upjohn Company Oxazole [2,3-c]-coumarin
EP0243449A1 (en) 1985-10-18 1987-11-04 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US5373095A (en) 1985-10-18 1994-12-13 The Upjohn Company Steroid compounds
US5001234A (en) 1987-04-16 1991-03-19 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US5306830A (en) 1989-04-27 1994-04-26 The Upjohn Company Substituted 3-amino chromans
US5144045A (en) 1990-11-13 1992-09-01 American Cyanamid Company Phosphocholine derivative inhibitors of phospholipase A2
US5208223A (en) 1990-11-13 1993-05-04 American Cyanamid Company Phosphocholine derivative inhibitors of phospholipase A2
US5234933A (en) * 1991-10-31 1993-08-10 Board Of Governors Of Wayne State University And Vanderbilt University Cyclic hydroxamic acids
EP0584374B1 (en) 1992-03-11 1997-09-24 Kyowa Hakko Kogyo Co., Ltd. Peptide which inhibits phospholipase c
DE4210332C1 (es) 1992-03-30 1993-07-15 Gruenenthal Gmbh, 5100 Aachen, De
US5238832A (en) 1992-06-08 1993-08-24 Board Of Governors Of Wayne State University Aryl aliphatic acids
AU5076293A (en) 1992-12-04 1994-06-16 F. Hoffmann-La Roche Ag Hispidospermidin
US5360815A (en) 1993-06-23 1994-11-01 Merck Frosst Canada, Inc. Heteroaryl cinnamic acids as inhibitors of leukotriene biosynthesis
US5519163A (en) 1993-10-15 1996-05-21 Merck & Co., Inc. Inhibitors of phosphoinositide-specific phospholipase C
US5942246A (en) 1996-02-16 1999-08-24 The Liposome Company, Inc. Etherlipid containing multiple lipid liposomes
PT1019068E (pt) 1996-09-11 2009-10-08 Elizabeth Shanahan-Prendergast Formulações terapêuticas contendo veneno de serpente e/ou insecto para a profilaxia e terapia de neoplasmas
IL137672A0 (en) 2000-08-03 2001-10-31 Dpharm Ltd Derivatives of branched-chain lipophilic molecules and uses thereof

Also Published As

Publication number Publication date
ATE348622T1 (de) 2007-01-15
WO2002030408A3 (en) 2003-11-06
ATE496619T1 (de) 2011-02-15
AU2002224354A1 (en) 2002-04-22
ES2276847T3 (es) 2007-07-01
EP1379235B1 (en) 2006-12-20
CA2425215A1 (en) 2002-04-18
DK1754480T3 (da) 2011-05-16
DE60143975D1 (de) 2011-03-10
EP1754480A3 (en) 2007-05-09
CA2425215C (en) 2009-12-29
EP1754480B1 (en) 2011-01-26
JP2004532795A (ja) 2004-10-28
WO2002030408A2 (en) 2002-04-18
DK1379235T3 (da) 2007-01-29
US7713949B2 (en) 2010-05-11
DE60125420D1 (de) 2007-02-01
US20020115641A1 (en) 2002-08-22
EP1754480A2 (en) 2007-02-21
DE60125420T2 (de) 2007-09-27
EP1379235A2 (en) 2004-01-14

Similar Documents

Publication Publication Date Title
EE04990B1 (et) HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod
DK1509232T3 (da) Kombination af en NMDA-antagonist og acetylcholin-esterase inhibitorer til behandling af Alzheimers sygdom
HUS1200030I1 (hu) Dipeptidil peptidáz IV ciklopropil-kondenzált pirrolidin-bázisú inhibitorai és eljárás elõállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
NO20040968L (no) Opioidagonistpreparater med frigjorbar og sekvestrert antagonist
HUP0300563A3 (en) Inhibitors of dipeptidyl peptidase iv, pharmaceutical compositions containing them and their use
WO2002011708A3 (en) Methods for inducing apolipoprotein e secretion
AU2002241736A1 (en) Method for preventing or treating pain by administering an endothelin antagonist
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
MXPA03005601A (es) Nuevos compuestos y composiciones como inhibidores de catepsina.
IS7315A (is) Útskipt díketópíperasín sem oxýtósínmótlyf
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
MXPA03002934A (es) Composiciones y metodos para aumentar la permeabilidad paracelular a traves de las barreras epiteliales y endoteliales.
MXPA02009176A (es) Tratamiento combinado con factor de crecimiento de queratinocito e inhibidor del factor de crecimiento epidermico.
WO2002087503A3 (en) Compositions and methods for treating colorectal polyps and cancer
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
SE9902597D0 (sv) New use
DE60130659D1 (de) Therapeutische verbindungen und verfahren
WO2001087281A3 (en) Method for enhancing cognitive function
DE60217315D1 (de) Pharmazeutische zusammensetzungen von rapamycines
EE200200556A (et) Midodriini ja/või desglümidodriini sisaldav kontrollitud vabanemisega farmatseutiline kompositsioon
NO20051261L (no) Morfin-6-glukuronidsalt
PT1276722E (pt) Inibidores de naftamidina-uroquinase
DE69824862D1 (de) Zusammenstellungen zur verbesserten wundheilung
WO2001055108A3 (en) Use of spl a2 inhibitors for the treatment of inflammation
AU2002211217A1 (en) Method of treating stroke